Summary p38 mitogen-activated protein kinases (MAPK) are a family of Ser/Thr kinases that regulate important cellular processes such as stress responses, differentiation, and cell-cycle control [1, 2] . Activation of MAPK is achieved through a linear signaling cascade in which upstream kinases (MAPKKs) dually phosphorylate MAPKs at a conserved 3-amino-acid motif (Thr-XTyr) [3] . G-protein-coupled receptor kinases (GRKs) are known to selectively phosphorylate G-proteincoupled receptors (GPCRs) and thus trigger desensitization [4, 5] . We report that GRK2 is a novel inactivating kinase of p38MAPK. p38 associates with GRK2 endogenously and is phosphorylated by GRK2 at Thr-123, a residue located at its docking groove. Mimicking phosphorylation at this site impairs the binding and activation of p38 by MKK6 and diminishes the capacity of p38 to bind and phosphorylate its substrates. Accordingly, p38 activation is decreased or increased when cellular GRK2 levels are enhanced or reduced, respectively. Changes in GRK2 levels and activity can modify p38-dependent processes such as differentiation of preadipocytic cells and LPS-induced cytokine release, enhanced in macrophages from GRK2 +/2 mice. Phosphorylation of p38 at a region key for its interaction with different partners uncovers a new mechanism for the regulation of this important family of kinases.
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Results and Discussion
p38MAPK Is Phosphorylated by GRK2, and Both Proteins Can Be Found in the Same Multimolecular Complex The activity and stability of GRK2 can be modulated by phosphorylation at specific residues by c-Src or by the ERK group of MAPK (see references in [4] ). ERK phosphorylation impairs GRK2 binding to Gbg subunits and causes a decrease in receptor phosphorylation [6, 7] . To investigate whether other MAPK cascades could also affect GRK2 functionality, we analyzed the cross phosphorylation between p38MAPK and GRK2 with in vitro kinase assays. Surprisingly, the presence of GRK2 markedly increased phosphate incorporation into GST-p38a ( Figure 1A ), whereas the opposite reaction was not observed. Heparin, a reported inhibitor of GRK2 but not the p38 inhibitor SB203580 ( Figure S1 in the Supplemental Data available online) specifically blocked this phosphorylation that was not taking place at the T 180 
GY
182 activation segment of p38 ( Figure S2 ). By utilizing increasing amounts of GST-p38 as a substrate, we estimated a Km value of approximately 80 nM and a maximal velocity of the reaction of 0.9 nmol/mg per min ( Figure S3 ). The quantified kinetic parameters are similar to those of biologically relevant GRK2 substrates, such as phosducin (40 nM [8] ) and b 2 -AR (260 nM [9] ), and improve the Km in the micromolar range reported for synucleins or tubulin [10, 11] .
Western-blot analysis revealed an activation-dependent association between p38 and GRK2 ( Figure 1B ) in cells cotransfected with a Flag-tagged p38 together with GRK2 and the b 2 -adrenergic receptor that was stimulated for 5 or 10 min with the b 2 -agonist isoproterenol. This association could also be observed with endogenous proteins ( Figures 1C and 1D ) and with other antibodies for immunoprecipitation of GRK2 instead of p38 (data not shown).
The Phosphorylation Site Is Located at the Docking Groove of p38 For proteomic identification of the phospho-acceptor site, we performed a MALDI-TOF analysis from tryptic peptides of GRK2-phosphorylated samples and RP-HPLC-coupled ES/MS-IT analysis in SIM-mode of the candidate peptide ( Figures S4, S5 , and S6; see also Supplemental Results). Site-directed mutagenesis of the identified residue, Thr-123 of mouse p38a, either to alanine or to aspartate, that mimics a covalently bound phosphate group and purification of the corresponding fusion proteins showed that neither GST-p38T123A nor GST-p38T123D could be phosphorylated by GRK2 ( Figure 1E ) and confirmed that threonine 123 is the phospho-acceptor site for GRK2 in p38.
Many MAPK substrates and interacting proteins share a common structure named D (docking) domain [12] . Recent X-ray crystallography studies of p38 in complex with peptides containing the D domains of MKK3b and *Correspondence: fmayor@cbm.uam.esMEF2A have allowed for the characterization of the docking domain where these proteins anchor [13] . Thr-123, the residue phosphorylated by GRK2 in p38, lies precisely at the entrance of this docking groove ( Figure  S7 ) where interactions are based mainly on hydrophobic contacts; mutations of Ile-116 and Gln-120, which lie in very close proximity to Thr-123 in the crystal structure, severely impair the docking of p38 partners [13] .
A p38 Mutant That Mimics Phosphorylation by GRK2 Displays Reduced Activation by MKK6, Decreased Activity toward Substrates, and Impaired Binding to Both Types of Partners The GST-p38T123A mutant is readily phosphorylated by MKK6 and shows clear activity toward ATF2 (Figure 2A ) or MEF2A ( Figure 2B ), although to a lesser extent than the wild-type GST-p38 protein. The GST-p38T123D mutant displays a severely impaired phosphorylation by MKK6 ( Figure 2A ) and markedly reduced activity toward these substrates (Figures 2A and 2B) . Furthermore, pulldown assays that utilizes purified GST-p38 mutants and MAPKAPK2 (MK2), as a specific substrate, or MKK6, as an activator, demonstrated that binding to both partners of the phosphorylation-mimicking mutant, T123D, is severely impaired, whereas T123A mutation has no evident effect on the direct association of substrates or activators to p38 ( Figure 2C ). On the other hand, upon ectopical expression of the p38T123D mutant, the in vivo phosphorylation by cotransfected active MKK6 in cultured cells was significantly reduced in the Flag-tagged p38T123D mutant compared to the corresponding wild-type p38 construct, whereas this effect was not observed for the T123A mutant ( Figure 2D ). These results confirm that the existence of a negatively charged residue in that particular position has very important consequences for the ability of MKK6 to associate to and activate p38 at the T 180 GY 182 in vitro and in cells and on the capacity of p38 to bind and phosphorylate its substrates. Our work demonstrates that introducing a negative charge inside this otherwise hydrophobic pocket can disrupt essential docking contacts and interferes with the p38 pathway at two levels: It can impede binding and p38 activation by upstream kinases, such as MKK6, and it can also affect association and phosphorylation of p38 substrates.
Cellular GRK2 Levels Correlate Negatively with p38 Activation
We next wanted to assess whether changes in cellular GRK2 levels would translate into a regulation of p38 activation. To avoid possible interferences of varying GRK2 levels on GPCR-mediated stimulation of p38, we studied p38 activation by a direct upstream modulator. MKK6-mediated phosphorylation of p38 at the activation segment decreases progressively as the cellular concentration of GRK2, but not that of a GRK2-K220R inactive mutant, gradually increases ( Figure 3A and Figure  S8 ). Immunoprecipitated p38 activity toward a peptide substrate upon MKK6 expression was also selectively impaired when this construct was coexpressed with increasing levels of GRK2 ( Figure 3B ). Together, these experiments demonstrated that changing GRK2 levels could regulate both the activation and the activity of p38 in cells. In Vitro, and Both Kinases Associate in an Agonist-Dependent Manner (A) Purified GRK2 (50 nM) was incubated for 30 min with g 32 P-ATP as specified in the Supplemental Experimental Procedures with GST-p38 as a substrate in the presence or absence of heparin (50 ng/ml) to inhibit GRK2 kinase activity. Autophosphorylation controls were incubated in the same conditions. Phospho-proteins resolved by SDS-PAGE were visualized by autoradiography ( 32 P). Western-blot analysis of the purified proteins utilized for in vitro kinase assays was performed with an anti-GST-GRK2 antibody [28] . (B) HEK293 cells transfected with pCDNA3-GRK2, pBC12BI-b 2 -AR, and pCDNA3-Flagp38a (1 mg per p60) were serum-starved and either treated or not treated with 10 mM Isoproterenol. Flag-p38 immunocomplexes (IP) were analyzed by western blotting (WB) as described in the Supplemental Experimental Procedures. Negative controls (CTR) were cells transfected without Flag-p38. (C) Endogenous p38 was immunoprecipitated (IP) from Monomac1 cells with p38 antibodies or control sera and blotted so that associated endogenous GRK2 is detected [28] . (D) HEK293 cells were stimulated with LPA (10 mM) for the times indicated and immunoprecipitated with p38 antibodies (IP). Coprecipitated endogenous GRK2 was detected by western blotting. (E) Purified GST-p38 (WT), GST-p38T123A (T123A), and GST-p38T123D (T123D) were used as substrates for GRK2-dependent in vitro phosphorylation ( 
Phosphorylation of T123 of p38 in Cells
To further confirm that GRK2 modulates p38 via T123 phosphorylation, we generated a purified anti-phospho-T123 antibody by utilizing a peptide corresponding to the phosphorylated sequence of murine p38a and characterized it (see Figures S9 and S10). Increased GRK2 expression leads to enhanced phospho-T123-p38 (Figure 3C) . The lack of a specific pharmacological inhibitor for GRK2 forced us to use a kinase-deficient mutant of GRK2, K220R, to reduce endogenous GRK2 activity. As seen in Figure 3C , a decreased amount of pT123-p38 was detected in HEK293 cells overexpressing K220R-GRK2. We were also able to detect endogenous p38 phosphorylated in T123 in lysates or, more clearly, in immunoprecipitates of p38 from other cell types such as 3T3L1 fibroblasts, mouse macrophages (see below), and (A) In vitro kinase assays were performed with GST-p38WT, GST-p38T123A, and GSTp38T123D (150 nM) as substrates for MKK6 CAM (40 ng) and as kinases for GST-ATF2. Reactions and phospho-protein visualization ( 32 P) and total protein controls (Coomassie Brilliant Blue staining, CBB) were performed as in Figure 1. (B) GST-p38WT, GST-p38T123A (T123A), and GST-p38T123D (T123D) activated by MKK6 CAM were used to phosphorylate GST-MEF2A (2 mg, 32 P). (C) GST-p38 and its T123 mutants (300 nM) were incubated in the presence of purified MKK6 (3 nM) or His-tagged MAPKAPK2 (MK2, 20 nM) in a pull-down assay with GST as a negative control. Sedimented proteins were developed by western blotting with anti-MKK6, anti-Histidine (for His-MK2) or anti-GST (for total amounts of GST-p38s). (D) p38T123D displays reduced activation by MKK6 in situ. HEK293 cells seeded in M6 were transfected with 150 ng of pCDNA3-Flag-p38WT, pCDNA3-Flag-p38T123D, or pCDNA3-T123A plus 50 ng of MKK6 CAM , (+) or empty pCDNA3 (2) . p38 activation by MKK6 was evaluated in cotransfected Flag-p38. Data are from three independent experiments and refer to the activation obtained in the absence of MKK6 where 100% represents the activation of p38WT. *, p < 0.0001. In all panels, results are representative of three independent experiments generally performed in duplicate. Figure 3 . Increased Levels of GRK2 Modulate p38 Activation by MKK6 CAM and p38 Activity in Cells (A) HEK293 cells were transiently transfected in M6 with pCDNA3-Flag-p38a (100 ng), pCDNA3-MKK6 CAM (100 ng), or empty pCDNA3 (CTR) and increasing amounts of pCDNA3-GRK2 (25-1000 ng DNA) completed with pCEFL-EGFP. Lysates were analyzed for the amount of GRK2 overexpressed (GRK2) and the activation levels of p38 (Pp38(TGY)) and of total Flag-p38 (p38). Data in the bar graph are normalized to total p38 levels and refer to the activation obtained in the absence of GRK2 (100%). (B) HEK293 cells were transfected in duplicate with pCDNA3-Flag-p38a, pCDNA3-MKK6 CAM , or empty pCDNA3 (CTRL) and with 1 or 2 mg of pCDNA3-GRK2 (+) or pCEFL-EGFP (2). Immunoprecipitated Flag-p38 was subjected to an in vitro kinase assays with a specific peptide substrate (APRTPGGRR, 1 mM) as described in the Supplemental Experimental Procedures. SB203580 (0.5 mM) was added to some reactions (+SB).
32 P incorporation referred to levels found in the absence of MKK6 CAM (CTR), once similar immunoprecipitation of Flag-p38 was confirmed, as shown in the inset. (C) HEK293 cells were transfected with pCDNA3-Flag-p38a and either pCDNA3-GRK2 (GRK2) or pCDNA3-GRK2-K220R (K220R) with pCDNA3 as a control (CTR). Immunoprecipitated Flag-p38 phosphorylated at T123 was detected with a 1:200 dilution of the purified anti-phospho-T123 antiserum (P-T123flagp38). (D) Differentiated 3T3L1 preadipocytic cell lysates were collected at the indicated days after initiation of treatment. Levels of each protein and phosphorylated epitopes were visualized by western blotting.
from Monomac1 monocytic cells and mouse splenocytes (data not shown); these findings corroborate the fact that GRK2 protein levels and/or activity correlate with the phosphorylation of the T123 residue in p38.
The differentiation of 3T3L1 fibroblasts into adipocytic-like cells is a well-established phenomenon that is strictly dependent on p38 activation (see Figure 4 and [14, 15] ). We could observe that the decrease in phospho-TGY described to occur along the differentiation procedure [15, 16] parallels an increase in the phospho-T123 signal of endogenous p38 and in the levels of GRK2 ( Figure 3D ) and thus establishes a possible role for T123 phosphorylation in the progressive downregulation of p38 activation.
GRK2 Modulates p38-Dependent Physiological Processes
To further investigate this phenomenon, we generated populations of 3T3L1 cells stably overexpressing similar levels of either GRK2 or the K220R-GRK2 mutant. Figures 4A and 4B show less differentiating cells when higher levels of GRK2 are expressed (57.9 6 26.7 adipocytic cells per field in control cells versus 22.3 6 7.5 in GRK2-expressing cells). In sharp contrast, cells stably expressing K220R differentiated very efficiently into adipocytes (84 6 23 cells per field). Inhibiting GRK2 function may itself promote this phenomenon in a p38-dependent manner because the differentiation process was blocked when 30 mM SB203580 was regularly added to the cell media in every case ( Figure 4B ). This effect seems to be mediated via T123 phosphorylation because an exogenously expressed T123D mutant of p38 sensibly decreases the number of differentiated adipocytes among transfected 3T3L1 cells ( Figure S11 ). Overall, these results indicate that changing GRK2 levels or activity has an impact on this p38-dependent cellular process.
LPS-induced cytokine production has been extensively utilized as a model phenomenon in the study of the biological consequences of altering the p38 route [17, 18] . Because GRK2-deficient mice are embryonically lethal [19] , we utilized heterozygous GRK2 +/2 C57BL/6 mice (expressing some 40% less GRK2, Figure 4D ) to isolate peritoneal macrophages and analyzed these cells ) or mice heterozygous for GRK2 ( +/2 ) and starved for 2 hr; LPS (0.5 mg/ml) was added to stimulate TNFa production. Secreted TNFa was quantified with an ELISA assay. SB203580 (30 mM) was added to some wells 30 min before LPS. Mean values 6 SD are shown corresponding to ten different mice from four separate determinations. Data depict the amount of TNFa secreted by 10 6 cells in ng/ml. *, p < 0.005 (two-tailed Student's t test). (D) Macrophages were lysed and analyzed for p38 activation with different LPS concentrations with anti-P-TGY-p38, plus anti-p38 and anti-actin. Levels of endogenous total GRK2 in macrophage lysates as well as T123-phosphorylated-p38 in immunoprecipitates are shown in the inset. Experiments are representative of at least three similar determinations.
p38 Inhibition by Phosphorylation at Its Docking Sitefor LPS-dependent TNFa secretion. Increasing concentrations of LPS induced a more potent endogenous p38 activation in GRK2 +/2 macrophages than in wild-type littermates ( Figure 4C) . A more pronounced p38 activation by upstream regulators was also observed when we decreased GRK2 levels in a cell line by using an antisense strategy ( Figure S12) . TNFa production by macrophages obtained from GRK2 +/2 mice was significantly higher than that in wild-type cells (40.38 6 7.18 ng/ml in GRK2 +/2 versus 22.10 6 4.6 ng/ml in GRK2 +/+ macrophages), consistent with a decreased amount of endogenous p38 phosphorylated at T123. In agreement with several previously described reports [18] , this process is strictly dependent on a functional p38 in light of the fact that SB203580 completely abolished TNFa secretion ( Figure 4D ). Together, these results demonstrate that decreased levels of GRK2 are able to upregulate p38 activation and p38-dependent cellular processes such as cytokine secretion.
Regulation by phosphorylation of the docking interactions of MAPK family members with different partners has been documented in recent years. Phosphorylation of the D domain of PTP-SL by PKA inhibits its association to ERK1/2 and p38a [20] , and binding of MEKK1 to JNK has been shown to be regulated by PAK phosphorylation at Ser-67 of MEKK1 [21] . Our report builds on this novel concept of phosphorylation-dependent interactions by demonstrating that they can take place not only in the D domain of interacting partners but also inside the docking domains of the MAPK itself. Our report defines GRK2 as a kinase upstream of p38 that acts as an ''inactivating MAPKK,'' and this may have important consequences in the regulation of p38 activation subsequent or concomitant to stimuli that potentiate GRK2 activity such as GPCRs. GRK2 control of p38 activation and activity could potentially affect a wide variety of substrates and regulators of p38, namely those acting via docking interactions.
The lack of a specific, commercially available pharmacological inhibitor for GRK2 makes it necessary to overexpress GRK2, decrease its expression by different means, or use a kinase-dead mutant so that endogenous GRK2 activity can be downregulated and the physiological relevance of this kinase in vivo can be analyzed. In fact, our experimental elevation or decrease of GRK2 levels mimics what is found during the onset or development of certain pathologies (see below). By using these approaches, we demonstrate that the levels of GRK2 influence the outcome of physiological processes mediated by p38. In particular, the differentiation of the preadipocytic 3T3L1 cell line is impaired in cells with elevated levels of GRK2 and increased in GRK2-K220R-expressing cells. It is important to highlight here that this differentiation process is strictly dependent on p38 activity [14] and that an active MKK6 is able per se to trigger this phenomenon [15] . Thus, this model establishes how GRK2 levels are able to regulate p38-mediated processes in a kinase-activity-dependent manner. In addition, p38-dependent cytokine secretion upon inflammatory stimulation in isolated macrophages appears to also be altered when the cellular complement of GRK2 is decreased, in heterozygous mice, in a process that parallels differences in the observed p38 activation by LPS.
The opposing correlation between GRK2 levels and p38 activation suggested by our studies may have important patophysiological consequences. Interestingly, GRK2 levels and activity are increased in congestive heart failure and other cardiac pathologies [22] . Also, p38 itself has been implicated in the onset or progression of cardiac failure seemingly by regulation of processes such as cardiac remodelling, gene expression and contractility among others (reviewed in [23] ). Most interestingly, several studies have shown that p38 activity happens to be reduced in end-stage-failing myocardium in humans [24] , whereas the elevation of GRK2 levels appears to be an early event of human cardiac failure (see references in [22] ). In striking accordance, activation of p38 has long been shown to be critical for the development of various inflammatory processes including rheumatoid arthritis, pulmonary illnesses, and inflammatory bowel disease, and its pharmacological inhibition emerges as a successful strategy for the treatment of these pathologies [17] . Precisely, samples from animal models of adjuvant-induced arthritis [25] or human samples of several chronic inflammatory diseases such as rheumatoid arthritis and multiple sclerosis [26, 27] exhibit a significant reduction of GRK2 levels, and this finding also points to a functional role for GRK2 in the control of p38 activation.
In sum, in this report, we uncover a novel mechanism for inactivating p38MAPK based on the phosphorylation by GRK2 at the entrance of the docking groove. We have found that GRK2 directly phosphorylates murine p38a at T123, highly conserved in other species and also present as a serine or a threonine in most mammalian p38s. Mimicking phosphorylation at this residue interferes both with the ability of p38 to bind and become phosphorylated by MKK6 in vitro and in cells and with the association and activity of p38 toward different substrates in vitro. Interfering with the cellular complement of GRK2, either overexpressing the exogenous kinase or decreasing its endogenous levels or activity, alters the activation of p38 by MKK6 and modifies the extent of phosphorylation at T123 both in endogenous and exogenously expressed p38, as assessed by an specific phospho-antibody. Moreover, we describe how changes in GRK2 levels can modify p38-mediated cellular processes, such as the differentiation of preadipocytic cells and the secretion of TNFa upon LPS stimulation, which is increased in GRK2 +/2 murine macrophages. This new mechanisms of modulation of p38MAPK pathway may contribute to the understanding of the negative correlation between GRK2 levels and the activation state of p38 observed in cardiovascular or inflammatory pathologies [17, 23] . 
